Barclays’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $160M | Sell |
256,192
-56,901
| -18% | -$38.7M | 0.03% | 368 |
|
|
2026
Q1 | $242M | Buy |
313,093
+1,926
| +0.6% | +$1.47M | 0.06% | 247 |
|
|
2025
Q4 | $240M | Sell |
311,167
-14,754
| -5% | -$10M | 0.06% | 246 |
|
|
2025
Q3 | $183M | Sell |
325,921
-157,105
| -33% | -$88.8M | 0.04% | 319 |
|
|
2025
Q2 | $254M | Buy |
483,026
+161,669
| +50% | +$90.2M | 0.06% | 222 |
|
|
2025
Q1 | $204M | Sell |
321,357
-63,821
| -17% | -$43.9M | 0.06% | 248 |
|
|
2024
Q4 | $274M | Sell |
385,178
-27,569
| -7% | -$23.1M | 0.08% | 170 |
|
|
2024
Q3 | $434M | Buy |
412,747
+62,632
| +18% | +$69.7M | 0.12% | 130 |
|
|
2024
Q2 | $368M | Buy |
350,115
+6,497
| +2% | +$6.3M | 0.11% | 135 |
|
|
2024
Q1 | $331M | Buy |
343,618
+45,381
| +15% | +$43.2M | 0.12% | 145 |
|
|
2023
Q4 | $262M | Buy |
298,237
+43,367
| +17% | +$35.7M | 0.1% | 188 |
|
|
2023
Q3 | $210M | Sell |
254,870
-24,114
| -9% | -$19M | 0.13% | 168 |
|
|
2023
Q2 | $200M | Buy |
278,984
+102,689
| +58% | +$79.2M | 0.13% | 159 |
|
|
2023
Q1 | $145M | Sell |
176,295
-51,879
| -23% | -$39.1M | 0.07% | 194 |
|
|
2022
Q4 | $165M | Buy |
228,174
+72,348
| +46% | +$53.4M | 0.07% | 189 |
|
|
2022
Q3 | $107M | Buy |
155,826
+35,584
| +30% | +$22.4M | 0.12% | 168 |
|
|
2022
Q2 | $71.1M | Sell |
120,242
-40,548
| -25% | -$26.4M | 0.04% | 289 |
|
|
2022
Q1 | $112M | Sell |
160,790
-328,819
| -67% | -$208M | 0.09% | 220 |
|
|
2021
Q4 | $309M | Buy |
489,609
+172,347
| +54% | +$106M | 0.12% | 145 |
|
|
2021
Q3 | $192M | Buy |
317,262
+139,464
| +78% | +$86.6M | 0.09% | 186 |
|
|
2021
Q2 | $99.3M | Buy |
177,798
+19,565
| +12% | +$9.91M | 0.05% | 298 |
|
|
2021
Q1 | $74.9M | Sell |
158,233
-14,949
| -9% | -$7.28M | 0.04% | 339 |
|
|
2020
Q4 | $83.7M | Buy |
173,182
+29,514
| +21% | +$15.9M | 0.04% | 300 |
|
|
2020
Q3 | $80.4M | Sell |
143,668
-23,180
| -14% | -$14.1M | 0.05% | 271 |
|
|
2020
Q2 | $104M | Buy |
166,848
+1,598
| +1% | +$907K | 0.08% | 184 |
|
|
2020
Q1 | $80.7M | Sell |
165,250
-77,090
| -32% | -$31.8M | 0.06% | 200 |
|
|
2019
Q4 | $91M | Sell |
242,340
-23,854
| -9% | -$8.03M | 0.05% | 292 |
|
|
2019
Q3 | $73.8M | Buy |
266,194
+74,612
| +39% | +$22.1M | 0.05% | 321 |
|
|
2019
Q2 | $60M | Buy |
191,582
+69,291
| +57% | +$23.1M | 0.04% | 426 |
|
|
2019
Q1 | $50.2M | Buy |
122,291
+2,642
| +2% | +$1.09M | 0.03% | 443 |
|
|
2018
Q4 | $44.7M | Sell |
119,649
-39,872
| -25% | -$14.6M | 0.03% | 415 |
|
|
2018
Q3 | $64.5M | Buy |
159,521
+26,444
| +20% | +$10.1M | 0.04% | 322 |
|
|
2018
Q2 | $45.9M | Sell |
133,077
-69,608
| -34% | -$21.8M | 0.04% | 390 |
|
|
2018
Q1 | $69.8M | Buy |
202,685
+42,672
| +27% | +$14.8M | 0.05% | 310 |
|
|
2017
Q4 | $60.2M | Sell |
160,013
-31,834
| -17% | -$12.9M | 0.05% | 329 |
|
|
2017
Q3 | $85.8M | Buy |
191,847
+116,822
| +156% | +$55.6M | 0.09% | 180 |
|
|
2017
Q2 | $36.8M | Buy |
75,025
+6,990
| +10% | +$3.06M | 0.04% | 375 |
|
|
2017
Q1 | $26.4M | Sell |
68,035
-31,750
| -32% | -$11.8M | 0.03% | 454 |
|
|
2016
Q4 | $36.6M | Buy |
99,785
+38,448
| +63% | +$14.6M | 0.04% | 351 |
|
|
2016
Q3 | $24.7M | Sell |
61,337
-21,452
| -26% | -$8.61M | 0.03% | 457 |
|
|
2016
Q2 | $28.9M | Sell |
82,789
-15,238
| -16% | -$5.87M | 0.04% | 386 |
|
|
2016
Q1 | $35.3M | Sell |
98,027
-27,797
| -22% | -$11.5M | 0.05% | 311 |
|
|
2015
Q4 | $68.2M | Sell |
125,824
-12,836
| -9% | -$6.95M | 0.08% | 205 |
|
|
2015
Q3 | $64.5M | Buy |
138,660
+47,728
| +52% | +$25.6M | 0.08% | 217 |
|
|
2015
Q2 | $46.4M | Sell |
90,932
-74,999
| -45% | -$36.6M | 0.05% | 311 |
|
|
2015
Q1 | $74.8M | Buy |
165,931
+60,642
| +58% | +$25.7M | 0.09% | 216 |
|
|
2014
Q4 | $43.2M | Buy |
105,289
+23,116
| +28% | +$9.09M | 0.04% | 404 |
|
|
2014
Q3 | $29.6M | Sell |
82,173
-23,578
| -22% | -$7.9M | 0.03% | 538 |
|
|
2014
Q2 | $29.8M | Sell |
105,751
-26,078
| -20% | -$7.73M | 0.03% | 502 |
|
|
2014
Q1 | $39.5M | Buy |
131,829
+3,453
| +3% | +$1.06M | 0.04% | 375 |
|
|
2013
Q4 | $35.3M | Sell |
128,376
-12,375
| -9% | -$3.56M | 0.04% | 479 |
|
|
2013
Q3 | $43.9M | Buy |
140,751
+28,479
| +25% | +$7.49M | 0.05% | 333 |
|
|
2013
Q2 | $25.2M | Buy |
+112,272
| New | +$26.1M | 0.03% | 530 |
|
Other funds holding REGN
Barclays's REGN Position: Q2 2026 in Review
Barclays reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, selling an estimated $38.7M and leaving 256,192 shares worth $160M. The position accounts for 0.03% of the portfolio, ranked #368.
Barclays first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $434M in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Barclays held 256,192 shares of Regeneron Pharmaceuticals worth $160M as of Q2 2026.
- Barclays sold 56,901 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $38.7M.
- Regeneron Pharmaceuticals made up 0.03% of Barclays's portfolio in Q2 2026, its #368 holding.
- Barclays first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Barclays's Regeneron Pharmaceuticals position peaked at $434M in Q3 2024.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.